Company intelligence / Profile preview

GENSPEED Biotech

Rainbach im Mühlkreis, Upper Austria, Austria

Ownership: Private
Employees: ~14
Development stage: Other

Overview

GENSPEED Biotech’s CE-IVD certified multiplex point-of-care platform is commercialized with robust published clinical data: the COVID-19 IgG xPOC antibody test demonstrated 100% sensitivity in a university-led study; the TBE (FSME) antibody test showed a sensitivity of 99.3% and specificity of 100%. Multiple products are currently on the market and new tests are in co-development with partner companies.

Therapeutic areas: OtherInfectious DiseasesEndocrinology
Modalities: Diagnostic deviceNucleic acid assayProtein assay
Industry: Molecular Diagnostics

Partnerships

Virogates A/S (co-development of suPARnostic POC+)Various OEM test manufacturers, assay developers, and distribution partners worldwide

Beyond the preview

Go deeper on GENSPEED Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENSPEED Biotech.

Explore the full profile